

- Cost-utility of first-line actinic keratosis treatments was assessed in Finland for a two-year time-horizon using a cost-effectiveness modeling approach and payer perspective.
- Ingenol mebutate gels and methyl aminolevulinate photodynamic therapy (MAL+PDT) were modeled to have the best overall effectiveness in terms of quality-adjusted life-years gained.
- Ingenol mebutate gel 0.015% and 0.05% were robustly cost-effective treatments for actinic keratosis in face or scalp and in trunk or extremities, respectively.
- A quality-adjusted life-year gained with MAL+PDT was associated with relatively high costs, and imiquimod's 5% cost-effectiveness was uncertain based on the sensitivity analyses.
- More frequent applications of ingenol mebutate gels or other feasible topicals in primary health care setting can further improve their cost-effectiveness.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Leo Pharma. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).